Invivyd Inc (IVVD) Stock Price, Quote & News

Company Profile

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in pha...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 819 0080

Website: invivyd.com

Address:

1601 Trapelo Road, Suite 178, Waltham, United States

Jack696 Jul. 15 at 5:29 PM

$IVVD just as I predicted... Will be .50s heading into earnings. If report break even...only because of unstandard accounting practices

1 · Reply

Cosmos99 Jul. 15 at 4:27 PM

$IVVD The chairman for about a year now, kept touting the target of breakeven by end of June. At February presentation, he asked the CFO to reiterate it as to hold the CFO accountable. Benefit of the doubt for 1q2025. No more excuses. Fatigue of this stock!

0 · Reply

Bbbooo Jul. 15 at 3:23 PM

$IVVD people are just tired and there is no practical hype despite our niche enthusiasm in mini covid surge and whatever theory of lobbying of a 90m market cap company with the entire FDA. IVVD knows it, they know how much sales they made, they know the more they wait the worse it gets, private equity does not care, 80-90m company=peanuts. If IVVD does not pre-announce it means sales were not good in Q2. simple as that. stop the theory/hopes focus on financials.

1 · Reply

alexx013 Jul. 15 at 3:22 PM

$IVVD bought more @ 0.68xx

0 · Reply

Cosmos99 Jul. 15 at 2:41 PM

$IVVD inflation picks up, biotech indices tumbling, small and micro unprofitable biotech dumped. Invivyd, no pre announcement yet and no catalyst. It all plays into shorts/bears. Until breakout (news, earning), then stock likely languishing with downward pressure.

0 · Reply

trader2sde Jul. 14 at 6:50 PM

$IVVD COVID-19 returns to Bay Area at highest levels since winter 6 out of 9 San Francisco testing sites showed high levels of the virus https://www.sfgate.com/local/article/covid-19-returns-bay-area-high-levels-20768931.php

1 · Reply

AndyBiltz1 Jul. 14 at 11:39 AM

$IVVD sadly, it’s over. 😞

0 · Reply

trader2sde Jul. 14 at 12:16 AM

$IVVD https://www.cnn.com/2025/07/02/health/fda-covid-vaccines-prasad reminder... no more monopolistic positions for vaccines companies. so room is made for mabs.

0 · Reply

trader2sde Jul. 13 at 11:56 PM

$IVVD https://www.nih.gov/news-events/nih-research-matters/why-protective-antibodies-fade-after-covid-19-vaccines October 29, 2024 Why protective antibodies fade after COVID-19 vaccines

0 · Reply

trader2sde Jul. 13 at 11:55 PM

$IVVD https://news.cuanschutz.edu/medicine/tracking-feelings-covid-19-monoclonal-antibodies-early-days-pandemic researchers in the University of Colorado School of Medicine continue to investigate their effectiveness and usage, in large part because they may be used again should another public health crisis such as COVID arise. “We don't usually think of intravenous medications as an outpatient treatment for illnesses — that's not something we've commonly done before, but it's not an unreasonable thing to consider,” says Lindsey Fish, MD, associate professor of general internal medicine. “There may be times or particular illnesses or populations where this might be an important way for us to treat patients in the outpatient setting.”

0 · Reply

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jun 26, 2025, 7:01 AM EDT - 19 days ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

May 27, 2025, 7:01 AM EDT - 7 weeks ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 23, 2025, 7:01 AM EDT - 7 weeks ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 21, 2025, 9:30 AM EDT - 7 weeks ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 15, 2025, 11:08 AM EDT - 2 months ago

Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:01 AM EDT - 2 months ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 7:01 AM EDT - 2 months ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 13, 2025, 7:01 AM EDT - 2 months ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 12, 2025, 7:01 AM EDT - 2 months ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 8, 2025, 7:01 AM EDT - 2 months ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Apr 21, 2025, 7:01 AM EDT - 3 months ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Mar 26, 2025, 4:15 PM EDT - 3 months ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Mar 20, 2025, 8:01 AM EDT - 4 months ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Mar 5, 2025, 7:05 AM EST - 4 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Feb 24, 2025, 9:20 AM EST - 5 months ago

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

Feb 24, 2025, 7:05 AM EST - 5 months ago

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Feb 10, 2025, 7:00 AM EST - 5 months ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Feb 5, 2025, 9:30 AM EST - 5 months ago

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

Feb 4, 2025, 3:55 PM EST - 5 months ago

I See The Bull Case For Invivyd, But I'm Not Married To It

Feb 3, 2025, 6:55 AM EST - 5 months ago

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Jan 27, 2025, 7:01 AM EST - 6 months ago

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Jan 10, 2025, 7:01 AM EST - 6 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Nov 14, 2024, 2:15 PM EST - 8 months ago

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:05 AM EST - 8 months ago

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 7:01 AM EST - 8 months ago

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Nov 12, 2024, 8:30 AM EST - 8 months ago

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Nov 6, 2024, 8:01 AM EST - 8 months ago

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Nov 6, 2024, 7:01 AM EST - 8 months ago

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

Oct 29, 2024, 7:03 AM EDT - 9 months ago

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Oct 29, 2024, 7:01 AM EDT - 9 months ago

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Oct 16, 2024, 7:01 AM EDT - 9 months ago

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Oct 1, 2024, 7:01 AM EDT - 10 months ago

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

Sep 23, 2024, 7:01 AM EDT - 10 months ago

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

Sep 12, 2024, 7:01 AM EDT - 10 months ago

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Sep 5, 2024, 7:01 AM EDT - 11 months ago

Invivyd to Participate in Upcoming Investor Conferences

Sep 4, 2024, 7:01 AM EDT - 11 months ago

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

Sep 3, 2024, 7:01 AM EDT - 11 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

Aug 27, 2024, 7:01 AM EDT - 11 months ago

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Aug 14, 2024, 2:39 PM EDT - 11 months ago

Invivyd, Inc. (IVVD) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 8:01 AM EDT - 11 months ago

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

Jul 1, 2024, 7:01 AM EDT - 1 year ago

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jun 14, 2024, 7:01 AM EDT - 1 year ago

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

Jun 3, 2024, 4:01 PM EDT - 1 year ago

Invivyd to Participate at the Jefferies Global Healthcare Conference

May 31, 2024, 7:05 AM EDT - 1 year ago

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial

May 31, 2024, 7:00 AM EDT - 1 year ago

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

May 29, 2024, 7:00 AM EDT - 1 year ago

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

May 22, 2024, 7:00 AM EDT - 1 year ago

Invivyd Elects Two New Independent Members to its Board of Directors

May 13, 2024, 4:01 PM EDT - 1 year ago

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Jack696 Jul. 15 at 5:29 PM

$IVVD just as I predicted... Will be .50s heading into earnings. If report break even...only because of unstandard accounting practices

1 · Reply

Cosmos99 Jul. 15 at 4:27 PM

0 · Reply

Bbbooo Jul. 15 at 3:23 PM

1 · Reply

alexx013 Jul. 15 at 3:22 PM

$IVVD bought more @ 0.68xx

0 · Reply

Cosmos99 Jul. 15 at 2:41 PM

0 · Reply

trader2sde Jul. 14 at 6:50 PM

1 · Reply

AndyBiltz1 Jul. 14 at 11:39 AM

$IVVD sadly, it’s over. 😞

0 · Reply

trader2sde Jul. 14 at 12:16 AM

$IVVD https://www.cnn.com/2025/07/02/health/fda-covid-vaccines-prasad reminder... no more monopolistic positions for vaccines companies. so room is made for mabs.

0 · Reply

trader2sde Jul. 13 at 11:56 PM

$IVVD https://www.nih.gov/news-events/nih-research-matters/why-protective-antibodies-fade-after-covid-19-vaccines October 29, 2024 Why protective antibodies fade after COVID-19 vaccines

0 · Reply

trader2sde Jul. 13 at 11:55 PM

0 · Reply

trader2sde Jul. 13 at 2:54 AM

$IVVD https://www.cbsnews.com/news/covid-cases-likely-rising-half-of-states-cdc-estimates/ COVID cases likely rising in half of states, CDC estimates

0 · Reply

doubleyou2 Jul. 11 at 1:29 PM

$IVVD 👌 Slowly building...

0 · Reply

TWITLIEDETECTOR Jul. 9 at 4:44 AM

$IVVD just checking to see if I am losing my mind..... I read that these guys are finally saying they will break even this quarter...... can someone confirm or deny?

2 · Reply

gb2017384 Jul. 8 at 5:52 PM

$IVVD ,the ne is saying there is a new covid 19 variant going around called XFG ,and they advise you keep up with your covid 19 booster shot.

0 · Reply

trader2sde Jul. 8 at 2:44 PM

$IVVD https://www.nbcnews.com/health/health-news/rfk-jr-sued-pediatricians-medical-groups-covid-vaccines-rcna217218 will this force the FDA to give something like mabs instead of the vaccines ? anyway this is dem doctors vs reps doctors. ie half the country.

0 · Reply

trader2sde Jul. 8 at 2:28 PM

$IVVD is the market only considering IVVD as a covid play or making a mistake ?... mabs market is huge. (treatments for many diseases, cancers, viruses)

0 · Reply

Bbbooo Jul. 8 at 12:45 PM

$IVVD there is no excuse indeed. IVVD had all the time and full fieldforce to deliver in Q2. not making at least 20m would be a disgrace and frankly would just mean there is no market and IVVD cannot convince doctors and payers… making same or less vs Q4 would be a joke, it would trigger why they hired all these people and salesreps...

1 · Reply

Cosmos99 Jul. 8 at 11:11 AM

$IVVD By now, management should know whether they delivered on its target for breakeven in 2Q. They can pre announce it. If they don’t, then the risk of market perceiving it as missed (like what happened with 1Q number). They pre announced surprised 3Q and 4Q 2024, but remained silent for 1Q 2025 which turned out bad. If that target confirmed missed (at earning release), then the stock is broken and credibility lost. They deserved the benefit of the doubt for 1Q as internalising sales team. No more excuses; Pemgarda has no competition, gross margin above 90% and core market of at least 0.5m patients. Either there is no meaningful market size/demand or management unable to execute and deliver. If target is achieved, then expect revaluation for the stock from this depressed level. Consistent sequential growth and profit should propel the stock towards it analysts target $5-$9. Until the market gets clarity, the stock is likely languishing or facing down pressure.

1 · Reply

Jack696 Jul. 7 at 8:24 PM

$IVVD tomorrow we drop to .60s, then the .50s by the end of the month. News hasn't moved it much. Maybe It'll bounce back in August

0 · Reply

Wanggamza Jul. 7 at 5:27 PM

$IVVD is it dead..?

1 · Reply

trader2sde Jul. 4 at 5:33 AM

$IVVD https://www.cnn.com/2025/07/02/health/fda-covid-vaccines-prasad Top FDA vaccine official rejected broad use of Covid-19 shots, documents show By Sarah Owermohle , Brenda Goodman Updated 13 hr ago

0 · Reply

TheFnFortune Jul. 3 at 12:40 PM

$IVVD Trump just needs to say the magic word Monoclonal antibodies

0 · Reply

Market Cap	87.18M
Revenue (ttm)	25.38M
Net Income (ttm)	-169.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-669.54%
Debt to Equity Ratio	0.00

Volume	810,800
Avg Vol	1,976,262
Day's Range	N/A - N/A
Shares Out	119.96M
Stochastic %K	8%
Beta	0.52
Analysts	Strong Sell
Price Target	$5.95